Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa

NCT06301256 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the drug tirzepatide in adults with moderate to severe hidradenitis suppurativa to see if it reduces symptoms by at least 50%.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-03 · est. completion 2025-03

What this study is testing ClinicalTrials.gov NCT06301256 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the clinical efficacy and safety of tirzepatide in subjects with moderate to severe hidradenitis suppurativa. The study will be conducted over 24 weeks on active therapy followed by a eight-week observational follow-up visit. The total length of the study will be 32 weeks .

Treatments tested

TIRZEPATIDE Drug

Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.

Main thing measured	Hidradenitis Suppurativa Clinical Response (HiSCR) 50%
Sponsor	Florida Academic Centers Research and Education, LLC
Conditions studied	Hidradenitis Suppurativa
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06301256 ↗